ArriVent BioPharma, Inc. AVBP
13.49 USD 0.00 (+0.00%)
At closeNov 5, 2026, 9:06 AM EST
13.51 +0.02 +0.15%
Pre-market · Nov 5, 9:06 AM ET
Day range unavailable
11.36 52-week range 35.83
- YTD
- -32.95%
- 1 year
- -27.90%
Financial health
Altman Z-Score
12.30 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 2
Valuation
P/E -4.7×
FY 2021 5y median -9.2× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B 2.5×
FY 2021 5y median 3.3× FY 2025
P/FCF -4.8×
FY 2021 5y median -11.4× FY 2025
EV/EBITDA -4.4×
FY 2021 5y median -4.4× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -20.8%
FY 2021 5y median -8.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE -54.1%
FY 2021 5y median -45.8% FY 2025
ROIC -57.8%
FY 2021 5y median -36.6% FY 2025
ROA -49.9%
FY 2021 5y median -42.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income -88.2%
FY 2021 FY 2025
EPS (diluted) -68.8%
FY 2021 FY 2025
Free Cash Flow -128.7%
FY 2021 FY 2025
Financial Health
Current Ratio 12.8×
FY 2021 5y median 13.8× FY 2025
Quick Ratio 12.8×
FY 2021 5y median 13.8× FY 2025
Debt / Equity 0.0×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2021 5y median 0.7× FY 2025
Interest Coverage 0.0×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31